Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

NCT03081598 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

104

Enrollment

INDUSTRY

Sponsor class

Stopped Failure to meet recruitment target during the recruitment period

Conditions

Type 2 Diabetes Mellitus
Metabolic Syndrome

Interventions

DRUG: PBI-4050
OTHER: Placebo

Sponsor

Liminal BioSciences Ltd.